Login / Signup
Efficacy of in-class interleukin-23 inhibitor switching: risankizumab following guselkumab failure in moderate-to-severe psoriasis treatment.
R Reddy
S Pannu
K Fiumara
J Kahn
David Rosmarin
Published in:
The British journal of dermatology (2020)
Keyphrases
</>
early onset
high intensity
combination therapy
drug induced